Table 6: Xanthine oxidase activity (μU/g of cardiac sample; 𝑋 ± S . D .) in rat cardiac homogenates 4, 48, and 96 h after doxorubicin administration.

Time from DOX injection (h)Dose of DOX (mg/kg b.w.)MethimazoleANOVA
0.00000.001%0.025% 𝑃

42 5 2 . 0 0 ± 1 4 . 0 0 5 6 . 0 0 ± 1 7 . 1 0 4 7 . 0 0 ± 1 8 . 0 0 0.6229
5 4 3 . 0 0 ± 8 . 0 0 4 3 . 0 0 ± 1 4 . 5 0 4 7 . 0 0 ± 1 8 . 6 0 0.9680
15 5 7 . 0 0 ± 8 . 0 0 3 4 . 0 0 ± 2 . 9 0 *,# 1 0 1 . 0 0 ± 6 . 9 1 #,†0.0171

482 3 8 . 0 0 ± 1 7 . 1 0 5 6 . 0 0 ± 1 4 . 3 0 5 4 . 0 0 ± 1 6 . 6 0 0.1998
5 3 4 . 0 0 ± 1 0 . 6 0 6 6 . 0 0 ± 5 0 . 0 0 6 4 . 0 0 ± 1 7 . 4 0.0602
15 6 5 . 0 0 ± 3 7 . 0 0 5 4 . 0 0 ± 9 . 4 0 5 8 . 0 0 ± 1 5 . 7 0.9324

962 5 0 . 0 0 ± 1 6 . 8 0 6 7 . 0 0 ± 1 9 . 0 0 5 5 . 0 0 ± 2 4 . 6 0.3705
5 5 4 . 0 0 ± 3 2 . 7 0 6 0 . 0 0 ± 1 0 . 9 0 4 9 . 0 0 ± 1 8 . 0 0 0.3724
15 6 8 . 0 0 ± 3 3 . 6 0 5 2 . 0 0 ± 7 . 1 0 6 0 . 0 0 ± 1 2 . 6 0 0.6057
0.9% NaCl 𝟕 𝟎 . 𝟎 𝟎 ± 𝟑 𝟓 . 𝟖 𝟎 (control) 5 2 . 0 0 ± 1 0 . 7 0 4 6 . 0 0 ± 6 . 6 0

* 𝑃 < 0 . 0 5 versus control; #DOX + MET versus DOX; DOX + METH versus DOX + METL.